Back

Representativeness of EXPLORER-HCM trial and prevalence of eligibility criteria for Mavacamten in a nationwide cohort

29 August 2022 (16:10 - 16:20)
Organised by:
Congress Presentation Part of: Hypertrophic cardiomyopathy: not so rare, but not so easy Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Mariana Brandao

Hospital Universitario Puerta De Hierro Majadahonda, Madrid (Spain)

4 More presentations in this session

Presentation thumbnail
Metoprolol improves left ventricular longitudinal function at rest and during exercise in obstructive hypertrophic cardiomyopathy
Mrs A. Dybro (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Mavacamten induces a clinical, hemodynamic, and biomarker response beyond the primary endpoint in EXPLORER-HCM: results from a post hoc machine learning analysis
Doctor I. Olivotto (Florence, IT)
Abstract Slides Video
Presentation thumbnail
Prevalence and clinical correlates of clinical red flags for rare diseases in consecutive patients presenting with HCM phenotype
Doctor N. Maurizi (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Temporal trends, characteristics and comorbidities of patients with hypertrophic cardiomyopathy in denmark from 2005-2018: A nationwide cohort study.
Doctor C. Zoerner (Copenhagen, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy: not so rare, but not so easy

The Event

Event poster

ESC Congress 2022

29 August 2022 16:10 CET
You may be interested in
thumbnail
Congress Presentation
Cardiac myosin inhibitors use in the real world: what you need to know
thumbnail
Congress Presentation
Diagnostic challenges and persistent unmet therapeutic needs
thumbnail
Congress Presentation
Case study 2: navigating the complex waters

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources